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licenses/by/4.0/).Abstract Introduction: Variation in cyclophosphamide pharmacokinetics and metabolism
has been highlighted as a factor that may impact on clinical outcome in various tumour types.
The current study in children with B-cell non-Hodgkin’s lymphoma (NHL) was designed to
corroborate previous findings in a large prospective study incorporating genotype for common
polymorphisms known to influence cyclophosphamide pharmacology.
Methods: A total of 644 plasma samples collected over a 5 year period, from 49 B-cell NHL
patients 18 years receiving cyclophosphamide (250 mg/m2), were used to characterise a pop-
ulation pharmacokinetic model. Polymorphisms in genes including CYP2B6 and CYP2C19
were analysed.
Results: A two-compartment model provided the best fit of the population analysis. The mean
cyclophosphamide clearance value following dose 1 was significantly lower than following
dose 5 (1.83  1.07 versus 3.68  1.43 L/h/m2, respectively; mean  standard deviation from
empirical Bayes estimates; P < 0.001). The presence of at least one CYP2B6*6 variant allele
was associated with a lower cyclophosphamide clearance following both dose 1 (1.54  0.11 L/
h/m2 versus 2.20  0.31 L/h/m2, P Z 0.033) and dose 5 (3.12  0.17 L/h/m2 versus
4.35  0.37 L/h/m2, P Z 0.0028), as compared to homozygous wild-type patients. No phar-
macokinetic parameters investigated were shown to have a significant influence on progression
free survival.stitute for Cancer Research, Paul O’Gorman Building, Medical School, Framlington Place, Newcastle
4HH, United Kingdom. Tel.: þ44 0191 208 4332; fax: þ44 0191 208 3452.
(G.J. Veal).
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G.J. Veal et al. / European Journal of Cancer 55 (2016) 56e64 57Conclusion: The results do not support previous findings of a link between cyclophosphamide
pharmacokinetics or metabolism and disease recurrence in childhood B-cell NHL. While
CYP2B6 genotype was shown to influence pharmacokinetics, there was no clear impact on
clinical outcome.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The oxazaphosphorine alkylating agent cyclophospha-
mide is used across a wide range of tumour types in
childhood cancer [1,2]. In order for cyclophosphamide
to exert its antitumour activity, the prodrug requires
metabolic activation by hepatic cytochrome P-450
(CYP) enzymes to generate active alkylating species
[3,4]. Key enzymes involved in the initial metabolic step
to form 4-hydroxycyclophosphamide, include CYP2B6,
CYP2C19 and CYP3A4, expression of which can vary
markedly between individuals [5]. The active metabolite
4-hydroxycyclophosphamide exists in equilibrium with
its tautomeric form, aldophosphamide, with these me-
tabolites transported to tumour cells via the systemic
circulation [6]. Further spontaneous breakdown is
required to form the active DNA-crosslinking metabo-
lite, phosphoramide mustard, with the release of the
urotoxic metabolite, acrolein [7]. A number of inacti-
vating metabolic pathways may also play a role in
determining cyclophosphamide efficacy, leading to the
formation of 4-ketocyclophosphamide (KetoCP), dech-
loroethylcyclophosphamide (DCCP) and carbox-
yphosphamide (CXCP) [8]. The overall metabolism of
cyclophosphamide is therefore a complex process,
involving numerous enzymes which may vary in
expression and activity in cancer patients.
Variation in the metabolism of cyclophosphamide
between individuals has been highlighted as a factor that
may impact on clinical outcome, in terms of both
response and toxicity, in tumour types including breast
cancer in adults and non-Hodgkin’s lymphoma (NHL)
in children. A study carried out in the United Kingdom
(UK) by Yule et al., previously indicated that lower
clearance of cyclophosphamide to its active metabolites
was associated with an increased risk of disease recur-
rence in paediatric B-cell NHL patients. In addition,
likelihood of disease recurrence was positively related to
a higher formation of inactive metabolites following
cyclophosphamide administration [9].
A number of enzymes involved in the metabolism of
cyclophosphamide, including CYPs, UGT and GST
enzymes, may exhibit variable expression and activity
between patients which could impact on cyclophospha-
mide metabolism and/or clinical response and toxicity
[10]. Of particular note, CYP2B6 and CYP2C19 geno-
type have previously been shown to influencecyclophosphamide pharmacokinetics and activation, in
terms of half-life of the parent drug, in breast cancer
patients [11,12].
The current study in children with B-cell NHL was
designed to corroborate the findings of Yule et al. [9], in
a larger prospective study incorporating genotyping for
the common polymorphisms in genes known to influ-
ence the pharmacology of cyclophosphamide. While
high cure rates are commonly seen in B-cell NHL with
the use of cyclophosphamide-containing regimens [13],
it is important to investigate factors that influence
response rates and incidence of toxicity to further
improve outcome in childhood cancer.
2. Patients and methods
2.1. Patient eligibility and treatment
Patients 18 years or younger, receiving cyclophospha-
mide as part of their standard clinical treatment for B-
cell NHL, were eligible to participate in the trial. The
study was approved by the UK Trent Multicentre
Research Ethics Committee and registered through the
appropriate clinical trial registries (PK 2005 02 e REC
04/MRE04/68; CTA: 17136/0243/001; EUDRACT:
2004-003731-31) prior to patient recruitment. Partici-
pating centres obtained written informed consent, either
from patients or parents as appropriate, for all patients
entered onto the study. Patients were required to have
central venous access, in the form of double lumen
central venous catheters, in order to participate in this
pharmacokinetic study. Baseline toxicity data prior to
cyclophosphamide treatment, including baseline hae-
moglobin, white blood cell and platelet counts, were
obtained from patients’ notes and details of concomitant
medications prior to and/or in combination with cyclo-
phosphamide were recorded. Additional patient char-
acteristics and clinical parameters including glomerular
filtration rate, serum creatinine, alanine transaminase
(ALT) and bilirubin measurements were also collected
for post-study analysis.
Cyclophosphamide (250 mg/m2) was administered as
a 15 min infusion twice daily on days 2, 3 and 4 of
treatment (six doses in total) as part of the COPADM
regimen. This consisted of cyclophosphamide (1.5 g/m2
total dose as described, with hydration continued at
3000 ml/m2/day until 12 h after the final dose),
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day 1), prednisolone (60 mg/m2/day, days 1e7), doxo-
rubicin (60 mg/m2, 1e6 h infusion on day 2), high dose
methotrexate (3 g/m2, intravenous infusion over 3 h on
day 1), folinic acid (15 mg/m2 orally every 6 h, beginning
at 24 h from the start of methotrexate as required) and
intrathecal methotrexate/hydrocortisone (8e15 mg on
days 2 and 6). Toxicity following cyclophosphamide
treatment was assessed by the National Cancer Institute
Common Toxicity Criteria version 2.0. Progression free
survival data were obtained from 6 monthly follow-up
visits to the centre where treatment was undertaken.
2.2. Blood sampling and analysis
Blood samples (2.5 ml) for pharmacokinetic analysis
were obtained from a central line prior to administration
of the first dose of cyclophosphamide on day 2, at the
end of infusion and at 1, 2, 4, 6 and 12 h after the start of
infusion. Additional samples were obtained prior to
administration of the first dose of cyclophosphamide on
day 4 of treatment (dose 5), at the end of infusion and at
1, 2, 4, 6 and 12 h after the start of infusion of dose 5.
All samples were taken from a different lumen from that
used for drug administration following a standardised
procedure. Plasma was separated from whole blood
samples by centrifugation (1200g, 4 C, 10 min) and
stored at 20 C prior to analysis. Samples were sent by
overnight courier, on dry ice and in an insulated
container, to the Northern Institute for Cancer
Research, Newcastle University.
Concentrations of cyclophosphamide and its stable
inactivated metabolites, KetoCP, DCCP and
CXCP were measured in plasma using a validated LC/
MS method as previously described [14]. Cyclophos-
phamide was obtained from Sigma (Poole, Dorset). The
inactive metabolites and the internal standard deuter-
ated cyclophosphamide (D4CP) were obtained from IIT
(University of Bielefeld, Germany). The assay had a
limit of quantification of 0.5 mg/ml for cyclophospha-
mide and 0.05 mg/ml for the metabolites and exhibited
within- and between-run coefficients of variation and
bias below 15%. QC samples for each analyte were
included in each assay. Standard curves were linear be-
tween 0.5e10 mg/ml for cyclophosphamide and
0.05e1 mg/ml for CXCP, DCCP and KetoCP with r2
values  0.99. Samples containing concentrations of
cyclophosphamide or metabolites above the linear range
were diluted with blank plasma.
2.3. Pharmacokinetic analysis
A population pharmacokinetic model for cyclophos-
phamide was developed using nonlinear mixed effects
modelling (NONMEM version 7.2), based on the
enhancement of a model previously published by our
group [14]. The first order conditional estimationmethod with h/ 3 interaction was used, together with
ADVAN1/TRANS2 or ADVAN3/TRANS4 as appro-
priate. A composite error model was most appropriate
to describe within-subject error. An additive error
model, on the logarithmic scale, was used for inter-
individual variability in pharmacokinetic parameters.
As cyclophosphamide concentrations were available
from days 2 and 4 (doses 1 and 5) for each patient,
additional error terms were included to account for
inter-occasion variation (IOV) on clearance (CL) and
volume of distribution in the central compartment (V1).
The exact timing of the second dose administered on day
2 and of the doses administered on day 3 were not
recorded. Given this unknown dosing history, to allow
for non-zero cyclophosphamide concentrations prior to
the start of the first cyclophosphamide infusion on day
4, a rate-controlled steady-state ‘infusion’ into the cen-
tral compartment was assumed (terminating at the start
of the current infusion). This has the effect of initialising
all compartments with an appropriate amount of drug.
The rate of the ‘infusion’ was allowed to vary across the
population [15].
Allometric scaling was used for all population phar-
macokinetic parameters; the approach taken to this
scaling was the same as that used in a previously pub-
lished analysis [16]. Changes in NONMEM objective
function value (OFV), and examination of residual plots
guided model structure development. Empirical Bayes
estimates of pharmacokinetic parameters including CL,
V1 and cyclophosphamide area under the plasma
concentration-time curve (AUC) were obtained from the
final population model. The covariates body weight,
age, gender, ALT, bilirubin and creatinine, alongside
genetic variation including CYP2B6*6 genotype were
assessed for their relationship with CL.
Plasma concentrations of the inactive metabolites
CXCP, DCCP and KetoCP were determined on day 2
(dose 1) and day 4 (dose 5) of cyclophosphamide
treatment. Calculation of metabolite AUCs from time
0e6 h was carried out using the trapezoidal rule on day
2 (dose 1) and day 4 (dose 5).
2.4. Pharmacogenetics
Genomic DNA was obtained from whole blood samples
using Qiagen QIAamp DNA Blood Maxi kits ac-
cording to the manufacturer’s instructions. DNA purity
and concentration were measured using a NanoDrop
ND-1000 (Thermo Scientific, Rockford, United States
of America [USA]) and stored at 20 C prior to
pharmacogenetic analysis. Genotyping for SNPs
CYP2B6*5 1459C > T (rs3211371), CYP2B6*6
785A > G (rs2279343) & 516G > A (rs3745274),
CYP2C19*2 681G > A (rs4244285), CYP2C19*17-
806C > T (rs12248560), GSTP1*2 313A > G (rs1695),
CAR 540C > T (rs2307424) and PXR-25385C > T
(rs3814055) were performed using TaqMan probes and
Table 1
Patient characteristics.
Characteristic No. of patients %
Evaluable patients 49
Age (years)
3e8 13 26.5
8e12 13 26.5
11þ 23 47
Sex
Male 42 86
Female 7 14
Ethnicity
White British 42 86
White other 2 4
Asian Indian 1 2
Asian Pakistani 1 2
Mixed background 3 6
BW (kg)
Median 39.2
Range 16.3e138
BSA (m2)
Median 1.25
Range 0.69e2.2
Diagnosis
Burkitt’s lymphoma 42 86
Diffuse large B-cell lymphoma 7 14
BW e body weight; BSA e body surface area.
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Biosystems, California, USA) according to manufac-
turer’s instructions. Allelic discrimination was per-
formed using sequence detection software (Applied
Biosystems).
2.5. Statistical analysis
For the analysis of pharmacogenetic data, overall dif-
ferences between groups were assessed with the Man-
neWhitney and KruskaleWallis tests using GraphPad
Prism version 5.0 software (GraphPad Software, Inc.,
San Diego, CA, USA). Analysis of linkage disequilib-
rium was performed using Fisher’s exact test (two-sided)
for general contingency tables with SPSS version 15.0
software (SPSS Inc., Chicago, IL, USA). Time to disease
progression was calculated as the delay between the first
day of cyclophosphamide treatment and the first
observation of disease progression or death. Hazard
ratios for disease progression were estimated for indi-
vidual covariates using the univariate Cox proportional
hazards regression model approach, with each model
fitted separately. Potential prognostic factors were tested
as continuous variables. Statistical significance was
given for P values < 0.05.
3. Results
3.1. Patient characteristics and treatment
A total of 49 patients receiving cyclophosphamide as
part of their standard clinical treatment for B-cell NHL
were entered onto the study over a 5 year period. Pa-
tients were recruited from nine UK centres. The study
population had a median age of 11.7 years (range
3.5e18.7) and included 42 male and seven female pa-
tients. Patient characteristics including ethnicity, age,
sex and body weight are provided in Table 1.
3.2. Pharmacokinetics
A population pharmacokinetic analysis using data
collected from 48 patients on day 2 (dose 1) of cyclo-
phosphamide treatment and 46 patients on day 4 (dose
5) of treatment was performed using NONMEM.
Pharmacokinetic data were available following dose 1
and dose 5 from 45 patients, with a total of 644 plasma
samples available for analysis.
The best fit of the population analysis was obtained
with a two compartment model including random ef-
fects on CL, V1, Q and V2 allowing for correlation be-
tween CL and V1. The model included IOV for CL and
V1. Allometric scaling was used to allow for differences
in body size; population parameters are therefore scaled
to a standard body surface area of 1.4 m2. Mean (co-
efficient of variation) parameters were CL 2.2 (37%) L/h/
1.4 m2; V1 18.4 (25%) L/1.4 m
2; Q 5.2 (69%) L/h/1.4 m2and V2 21.8 (19%) L/1.4 m
2. Estimates of IOV were CL
18% and V1 21%. Estimates of the composite intra-
subject error model were 0.1 mg/ml and 14% for the
additive and multiplicative components respectively.
There was a significant increase in CL on day 4 (OFV
change of 116); on average CL increased by a factor of
2.1. No change was apparent for V1. The covariates
body weight, age, gender, ALT and bilirubin were not
observed to have a significant effect on cyclophospha-
mide pharmacokinetics. However, homozygous wild-
type CYP2B6 patients were shown to have on average
a 34% higher cyclophosphamide CL than patients with
at least one variant allele (OFV change 7.7). Creatinine
also had a relationship to CL (OFV change 10.6); as
creatinine increased, CL tended to decrease.
Table 2 provides a summary of empirical Bayes es-
timates of cyclophosphamide pharmacokinetic parame-
ters obtained from the final population model following
dose 1 and dose 5. The pharmacokinetic parameter es-
timates obtained were in general agreement with values
previously reported in the literature in paediatric patient
populations. Cyclophosphamide Cmax values were
observed between 15 min and 120 min following dose 1,
ranging from 9.8e114.6 mg/ml and between 15 min and
60 min following dose 5, ranging from 8.53e53.7 mg/ml.
The mean cyclophosphamide CL following dose 5 was
significantly greater than that following dose 1
(3.68  1.43 versus 1.83  1.07 L/h/m2, respectively;
p < 0.001). This shift in cyclophosphamide CL between
doses 1 and 5 resulted in a significantly lower cyclo-
phosphamide AUC following dose 5 (10.3  5.3 mg/
ml.min for dose 1 versus 4.7  1.7 mg/ml.min for dose 5,
Table 2
Cyclophosphamide pharmacokinetic parameters. Summary statistics for empirical Bayes estimates obtained from final population pharmaco-
kinetic model.
Study dose Age (years) BW (kg) BSA (m2) Dose (mg) CL (L/h/m2) V1 (L) AUC (mg/ml min)
1 11.2  4.0 40.8  22.5 1.24  0.38 314  95 1.83  1.07 17.3  8.2 10.3  5.3
5 11.3  4.0 41.1  21.9 1.25  0.37 314  92 3.68  1.43 17.4  7.9 4.7  1.7
BW e body weight; BSA e body surface area; CL e clearance; V1 e volume of distribution in the central compartment; AUC e area under the
plasma concentration-time curve; SD e standard deviation. All values indicate mean  SD.
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compartment (V1) was comparable following doses 1
and 5, with values of 17.3  8.2 and 17.4  7.9 observed,
respectively.
Cyclophosphamide metabolites CXCP, DCCP and
KetoCP could be quantified throughout the defined
pharmacokinetic sampling period in all patients studied.
A summary of cyclophosphamide metabolite AUC0e6h
values observed is provided in Table 3, with marked
inter-patient variability observed for all metabolites.
Significantly greater AUC0e6h values were seen
following dose 5 of cyclophosphamide treatment, as
compared to dose 1, for all metabolites measured
(CXCP e 198.9  137.9 mg/ml.min for dose 5 versus
103.7  60.9 mg/ml min for dose 1, p < 0.001; DCCP e
105.6  60.9 mg/ml min versus 76.7  49.6 mg/ml min,
p Z 0.008; KetoCP e 153.4  61.3 mg/ml min versus
63.6  27.5 mg/ml min, p < 0.001).
3.3. Pharmacogenetics
The impact of pharmacogenetic variation on cyclo-
phosphamide pharmacokinetics was investigated in all
49 patients studied, for whom both pharmacogenetic
and pharmacokinetic data were available. Seven variant
alleles of putative relevance for cyclophosphamide
disposition were analysed. The allele frequencies for
CYP2B6*5, CYP2B6*6, CYP2C19*2, CYP2C19*17,
GSTP1*2, CAR 540C > T and PXR-25385C > T were
in accordance with those observed previously in
Caucasian populations and were consistent with Hardy-
Weinberg equilibrium. For the 49 patients studied, theTable 3
Cyclophosphamide metabolite formation following doses 1 and 5 of treatm
patients.
Dose 1 AUC0e6h (mg/ml.m
CXCP DCCP
All patients (n Z 49) Mean 103.7 76.7
SD 60.9 49.6
Range 35.4e352 21.4e285
Alive no disease (n Z 38) Mean 103.9 70.1a
SD 63.2 37.6
Relapsed (n Z 9) Mean 102.4 122.0a
SD 47.1 92.2
CXCP e carboxyphosphamide; DCCP e dechloroethylcyclophosphamide;
area under the plasma concentration-time curve.
a DCCP AUC0e6h determined following dose 1 had a negative prognostnumber of individuals with each individual CYP geno-
type studied were as follows: *1/*1 (40), *1/*5 (7) and
*5/*5 (2) for CYP2B6*5; *1/*1 (21), *1/*6 (22) and *6/*6
(6) for CYP2B6*6; *1/*1 (34), *1/*2 (12) and *2/*2 (3)
for CYP2C19*2 and *1/*1 (37), *1/*17 (10) and *17/*17
(2) for CYP2C19*17. Supplemental Table A.1 shows the
individual genotype data and associated cyclophospha-
mide CL values for all patients studied. Relationships
between cyclophosphamide CL following doses 1 and 5
of treatment and CXCP, DCCP and KetoCP AUC
values and the studied genetic variants were investi-
gated. A significant effect of CYP2B6*6 on cyclophos-
phamide CL was observed. The presence of at least one
variant allele was associated with a lower cyclophos-
phamide CL following both dose 1 (1.54  0.11 L/h/m2
versus 2.20  0.31 L/h/m2, p Z 0.033) and dose 5
(3.12  0.17 L/h/m2 versus 4.35  0.37 L/h/m2,
p Z 0.0028) of treatment, as compared to homozygous
wild-type CYP2B6 patients. It should be noted that
within the CYP2B6*1/*1 patient group, there are a
number of patients who are carriers of other CYP2B6
variant alleles and similarly, within the CYP2B6*6 het-
erozygote group there are several patients who may be
carriers of the CYP2B6*7 variant allele (see
Supplemental Table A.1 for individual patient genotype
data). We have not attempted to further stratify the
patients into additional CYP2B6 groups based on
CYP2B6 genotype due to the limited number of patients
involved. No other statistically significant influence on
cyclophosphamide CL was found for any of the genetic
variants investigated, including the previously reported
effect of CYP2C19*17, although there was a trendent in study patients alive with no disease as compared to relapsed
in) Dose 5 AUC0e6h (mg/ml.min)
KetoCP CXCP DCCP KetoCP
63.6 198.9 105.6 153.4
27.5 137.9 60.9 61.3
19.9e141 90.6e921 37.5e287 69.8e353
62.2 199.0 100.4 148.1
26.4 144.4 55.6 58.9
71.5 198.1 138.7 182.5
34.5 97.5 86.8 70.9
KetoCP e ketocyclophosphamide; SD e standard deviation; AUC e
ic effect on progression free survival (p Z 0.05).
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at least one CYP2C19*17 variant allele following both
dose 1 (1.49  0.19 L/h/m2 versus 1.94  0.19 L/h/m2,
p Z 0.22) and dose 5 (3.12  0.36 L/h/m2 versus
3.86  0.25 L/h/m2, p Z 0.13), as compared to homo-
zygous wild-type CYP2C19 patients. Nor was there any
effect of genetic variation on CXCP, DCCP or KetoCP
AUC values observed following doses 1 or 5 of treat-
ment. Relationships between genotype for CYP2B6*6,
CYP2C19*17 and CYP2C19*2 and cyclophosphamide
CL following doses 1 and 5 of treatment are shown in
Fig. 1.
3.4. Clinical response
Of the patients studied, 38/49 (78%) were alive with no
disease at follow-up. The median time of follow-up was
6 years, with a range of 1e9 years. Of the remaining
patients, two (4%) were alive with disease progression
and seven (14%) had died following disease relapse orFig. 1. Effect of CYP2B6*6 genotype on cyclophosphamide clearance f
and CYP2C19*17 genotype on cyclophosphamide clearance following d
variant CYP2B6*6 allele was associated with a lower cyclophospham
(p Z 0.0028; panel B), as compared to homozygous wild-type CYP2B
mide CL was found for CYP2C19*17 or CYP2C19*2 (panels C and D
who are both *1/*2 and *1/*17.due to treatment-related deaths. The remaining two
patients were lost to follow-up. In the Cox proportional
hazards regression model, cyclophosphamide CL values
following doses 1 or 5 had no significant influence on
progression free survival. Cyclophosphamide metabolite
AUC0e6h values for patients alive with no disease and
those who relapsed are listed in Table 3. DCCP
AUC0e6h determined following dose 1 had a negative
prognostic effect on progression free survival (pZ 0.05).
However, this result should be treated with caution,
bearing in mind the borderline significance and the fact
that a total of eight variables were investigated. DCCP
AUC0e6h determined following dose 5 had no prog-
nostic effect on progression free survival (p Z 0.26).
Fig. 2 shows KaplaneMeier curves of progression free
survival according to (A) cyclophosphamide CL
following dose 1, (B) cyclophosphamide CL following
dose 5, (C) DCCP AUC0e6h following dose 1 and (D)
DCCP AUC0e6h following dose 5 of treatment, with
patients stratified above and below the median valuesollowing dose 1 (A) and dose 5 (B) of treatment, and CYP2C19*2
ose 1 (C) and dose 5 (D) of treatment. The presence of at least one
ide CL following both dose 1 (p Z 0.033; panel A) and dose 5
6 patients. No statistically significant influence on cyclophospha-
). The CYP2C19*2/*17 group (panels C and D) contains patients
Fig. 2. KaplaneMeier curves of progression free survival according to (A) cyclophosphamide clearance following dose 1, (B) cyclo-
phosphamide clearance following dose 5, (C) DCCP AUC0e6h following dose 1 and (D) DCCP AUC0e6h following dose 5. Patients with
values above and below the median are displayed as dashed lines and solid lines, respectively. DCCP, dechloroethylcyclophosphamide;
AUC, area under the plasma concentration-time curve.
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eters investigated were shown to influence progression
free survival. Similarly, there was no effect of genetic
variation on clinical outcome for any of the genetic
variants studied.
Mean DCCP AUC0e6h values following doses 1 and
5 were 74% and 38% higher, respectively, in patients
who relapsed as compared to patients who were alive
with no disease at long-term follow-up (dose
1  122.0  92.2 mg/ml min versus 70.1  37.6 mg/
ml min; dose 5  138.7  86.8 mg/ml min versus
100.4  55.6 mg/ml min). However, due to the level of
inter-patient variability exhibited and the small number
of patients in the relapsed group, these differences were
not statistically significant.
4. Discussion
The metabolic elimination of cyclophosphamide has
previously been identified as a factor which may influ-
ence exposure of both tumour and host tissues to active
species and thus affect clinical outcome [5,8e12]. Many
of these studies have been in adult cancer patients acrossa number of different tumour types. One study in pa-
tients with childhood B-cell NHL found that cyclo-
phosphamide CL and the extent of formation of inactive
metabolites influenced the likelihood of disease relapse
[9]. The current study was designed to corroborate these
results in a larger prospective study, and to incorporate
an investigation of genetic variants thought to influence
the pharmacology of cyclophosphamide. This allowed
us to address the hypothesis that pharmacogenetic
variability, mediated by an effect on cyclophosphamide
metabolism and pharmacokinetics, impacts on response
to treatment.
A total of 49 children with B-cell NHL were recruited
at nine UK centres over a 5 year period, with combined
information generated on cyclophosphamide pharma-
cokinetics, metabolism, pharmacogenetics and clinical
outcome. The length of time taken to complete the
current study highlights the challenges faced when car-
rying out clinical pharmacology studies in a paediatric
oncology setting, requiring the collection of serial blood
samples from patients with a particular tumour type,
receiving specific chemotherapeutics on a defined treat-
ment protocol. The main aim of the study was to
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the pharmacokinetics and metabolism of cyclophos-
phamide, based on existing pharmacokinetic and clinical
response data in a comparable patient population. In
contrast to the Yule study, no correlation was observed
between cyclophosphamide clearance following either
dose 1 or dose 5 of treatment and patient outcome, with
no difference in clearance observed in patients alive and
disease-free at long-term follow-up, as compared to
patients who had experienced disease relapse. While
cyclophosphamide pharmacokinetics were shown to be
influenced by CYP2B6*6 genotype, with the presence of
at least one variant allele associated with a lower
cyclophosphamide CL, the variations in cyclophospha-
mide CL observed had no apparent bearing on clinical
response. No other effect of pharmacogenetic variation
on cyclophosphamide pharmacokinetics or metabolite
formation was observed. Previous studies have reported
modest effects of both CYP2B6 and CYP2C19 genotype
on the pharmacokinetics of anticancer drugs, including
cyclophosphamide, with the impact being both dose
dependent and potentially influenced by disease status
[5,11,12,17e19].
The extent of cyclophosphamide metabolism in the
current study was comparable to data from previous
publications in children, with significant increases in
metabolite formation observed over several days of
treatment due to the induction of CYP enzymes [14,20].
Although DCCP AUC0e6h following dose 1 of treatment
was associated with worse progression free survival, the
level of significance and number of tests carried out warn
against drawing firm conclusions from this result. Simi-
larly, although DCCP AUC0e6h values following doses 1
and 5 of treatment were higher in patients who relapsed as
compared to patients who were alive with no disease at
long-term follow-up, these differences were not statisti-
cally significant. No other relationships between the
extent of cyclophosphamide metabolism and clinical
outcome were observed. Again, these data contrast with
the previous findings ofYule et al. in a comparable patient
population [9]. Although a more sensitive LCMS assay
was used in the current study, with a ten-fold lower limit
of quantification for cyclophosphamide metabolites, this
should not have influenced the ability to detect an un-
derlying difference in metabolite levels between relapse
and disease-free patients.
Other disparities between the current study and the
Yule et al. publication include differences in cyclophos-
phamide dose andpatient gender and a high percentage of
Burkitt’s lymphomapatients in the current study. A lower
dose of cyclophosphamide was administered to patients
in the current study (250mg/m2 versus 1000mg/m2) and a
lower percentage of females were included as compared to
the previous study (14% versus 42%, respectively).
Cyclophosphamide dose and gender have previously been
reported to influence both pharmacokinetics and meta-
bolism of the drug and therefore may explain thedifferences in findings between the two studies [20,21]. In
particular, the association between cyclophosphamide
pharmacokinetics and clinical outcome in breast cancer
patients was in the setting of high-dose chemotherapy
(6000mg/m2) [22]. Based on the potential for saturationof
metabolism at an increased dose of cyclophosphamide, it
is certainly possible that themore frequent administration
of lower drug doses in the current study may explain our
findings. Beyond these factors the patient populations
were comparable in terms of age ranges and other patient
characteristics. In terms of data analysis the current study
included the more robust use of a univariate Cox pro-
portional hazards regressionmodel to assess the impact of
cyclophosphamide pharmacokinetic parameters and
metabolite levels on clinical outcome, as opposed to the
direct comparison of median values between relapse and
remission patients in the previous study.
The current study involved quantification of cyclo-
phosphamide alongside its inactive metabolites, pre-
dominantly in an attempt to replicate the data generated
by Yule et al. [9] and recognising the difficulty of
accurately quantifying the unstable metabolites in a
multi-centre study. While other investigators have sug-
gested that CXCP (also known as CEPM) may be a
marker of cyclophosphamide bioactivation [23e25], in
the current study there was no link between CXCP
plasma concentrations and clinical outcome. Interest-
ingly, there were proportionally larger increases
observed in CXCP and ketoCP AUC0e6h values be-
tween cyclophosphamide dose 1 and dose 5, as
compared to the increase in DCCP AUC0e6h. Cyclo-
phosphamide auto-induction models have previously
been studied in some detail by Huitema et al. [26,27].
In summary, the findings of the current study do not
support a link between cyclophosphamide metabolism
and recurrence of disease in childhood B-cell NHL with
the cyclophosphamide dosing regimen described. While
the influence of CYP2B6 genotype on cyclophosphamide
pharmacokinetics was confirmed, there was no clear
impact of pharmacogenetic variation on clinical outcome.Role of the funding source
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